LOS ALTOS, Calif., September 12, 2023 – Alto Neuroscience Inc. today announced Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present at the following investor conferences:
Baird Global Healthcare Conference
Location: InterContinental New York Barclay
Presentation Date/Time: Wednesday, September 13, 2023, from 10:50-11:20 a.m. ET
Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
Location: Virtual
Private Company Panel Date/Time: Wednesday, September 20, 2023, from 1:00-1:50 p.m. ET
Jefferies Inaugural Biotech CNS/Neuro Summit
Location: Jefferies Conference Center, New York
Presentation Date: Wednesday, October 11, 2023
Leerink Partners Biopharma Private Company Connect
Location: Virtual
Date: October 25-26, 2023
During these conferences, members of the Alto leadership team will conduct meetings with registered attendees to highlight the company’s clinical development progress, recent data readouts, and upcoming milestones.
About Alto Neuroscience
Alto Neuroscience is pioneering precision psychiatry by developing targeted medicines to help patients get better faster. Differences in individuals’ biology impact how they respond to treatment. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, behavioral task performance, wearable data, genetics, and other factors to match each patient with the right Alto drug. The company’s work in identifying and categorizing core domains of mental function (cognition, emotion, and sleep processes) has resulted in a multiple modality approach that supports robust drug-response predictions. Alto’s clinical-stage pipeline includes first- or best-in-class novel drug candidates in depression, PTSD, and other mental health conditions, resulting in the broadest and most-advanced precision psychiatry effort. For more information, visit https://www.altoneuroscience.com or follow us on Twitter.
Investor Contact
Nick Smith
corporate@altoneuroscience.com
Media Contact
Jordann Merkert
